Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
-
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
-
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
-
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
-
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III programme in RA to include comparisons with current treatments across all studies in a range of RA patients.
-
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks.
-
U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review
TESARO, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ZEJULA (niraparib).
-
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
-
GSK announces data on anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma to be presented at European Hematology Association (EHA) Congress
GSK today announced new data on belantamab mafodotin will be presented at the 24th Congress of the European Hematology Association.
-
Nucala (mepolizumab) gains FDA approval for two new self-administration options
GSK today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab)
-
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion.
-
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
-
GSK changes sales representative incentive programme
We are announcing changes to our incentive programme for sales representatives in certain countries.
-
GSK’s strong science prominent at ATS 2019
More than 70 GSK abstracts presented
-
Update on Consumer Healthcare Joint Venture with Pfizer
The transaction between GSK and Pfizer Inc to create a Consumer Healthcare Joint Venture, was approved at a General Meeting held by GSK.
-
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
-
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
-
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV.
-
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
Recommendation based on GEMINI 1 & 2 studies which demonstrated non-inferior efficacy.
-
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)